Mostrando 2 resultados de: 2
Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
ArticleAbstract: Objective: To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11βPalabras claves:Autores:Belaya Z., Biller B.M.K., Feelders R.A., Fleseriu M., Houde G., Izquierdo M., Newell-Price J., Pedroncelli A.M., Pivonello R., Richard J. Auchus, Roughton M., Scaroni C., Shimatsu A., Vila G., Walia R.Fuentes:scopusRandomized Trial of Osilodrostat for the Treatment of Cushing Disease
ArticleAbstract: Context: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbiPalabras claves:11β-hydroxylase, Cushing disease, Hypercortisolism, OsilodrostatAutores:Belaya Z., Bex M., Carvalho D., Feelders R.A., Gadelha M., Gilis-Januszewska A., Heaney A.P., Ku C.H.C., Liao Z., Pedroncelli A.M., Richard J. Auchus, Roughton M., Snyder P.J., Witek P., Wojna J., Yu Y.Fuentes:scopus